Issue 23 - Jun 7, 2019
  • ASCO’s mCODE seeks to compose lingua franca for cancer informatics

    The American Society of Clinical Oncology published a set of common standards for cancer data elements via an initiative dubbed mCODE.

  • Conversation with The Cancer Letter

    ASCO’s Miller: mCODE will improve downstream analytics with essential cancer data elements

    The mCODE initiative, developed by American Society of Clinical Oncology and its partners, aims to optimize electronic health records to answer research questions on drug efficacy and patient outcomes.

  • Guest Editorial

    Big Data for outcomes and clinical research: major advance or improvement needed

    Creation of Big Data repositories is now emphasized at virtually all research institutions and the NIH, but the number of publications describing patient outcomes from these sources appears modest.1 Why is this so; what factors limit what should be a hugely productive resource, and how can we improve the impact of this use of Big Data? Why does this issue require greater physician engagement and understanding to solve? The integration of clinical, laboratory, and financial data is required to describe disease and treatment outcomes as well as treatment value.

  • Letter from the Editor

    ASCO 2019 through art

    This year, we decided to approach the annual meeting of the American Society of Clinical Oncology in a completely new way: through illustration.

  • Obituary

    Henry Lynch, pioneer of hereditary cancer detection, dies at 91

    Henry T. Lynch, the father of hereditary cancer detection and prevention, died June 2. He was 91.

  • In Brief

    • Tony Kerlavage named director of NCI CBIIT
    • Jeff Shilling named NCI’s chief information officer
    • Jeff Settleman named senior VP,  group head of oncology R&D  at Pfizer
    • RWJBarnabas Health and Rutgers Cancer Institute announce $750M cancer pavilion in New Brunswick
    • Hackensack Meridian Health opens Center for Discovery and Innovation
    • University of Indiana and MSK researchers receive $4.1 million grant from Cancer Moonshot
  • Funding Opportunities

    DoD kidney cancer funding opportunities for FY2019

    The FY19 Defense Appropriation provides $20 million to the Department of Defense Kidney Cancer Research Program to support research of exceptional scientific merit in the area of kidney cancer.  

  • TCCL Logo

  • Clinical Roundup

    • Study finds link between Medicaid expansion and equity in cancer care
    • Long-term survival benefit shown for metastatic melanoma patients treated with Tafinlar + Mekinist
    • Venclexta + Gazyva combination meets primary endpoint for CLL
    • Pembrolizumab found safe in treating cancer patients with HIV
    • BMS announces first presentation of results for Opdivo + Yervoy in hepatocellular carcinoma
    • Lymphoma trial finds combination targeted therapy effective prior to chemotherapy
    • Enfortumab vedotin produced tumor response rate of 44% in bladder cancer
    • Researchers identify three-drug combination curbing growth in melanoma
    • Taiho Oncology and Servier present Lonsurf data
  • Drugs & Targets

    • FDA grants Priority Review for daratumumab combination in multiple myeloma
    • Caris Life Sciences partners with Debiopharm International SA
  • NCI Trials

    NCI Trials for June

    The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

Issue 22 - May 31, 2019
Issue 21 - May 24, 2019
  • Trials & Tribulations

    Why I choose to play a dual role in TMIST

    As a physician-scientist, I have spent my career advancing research in women’s health. I was a part of the planning effort to design and launch TMIST—the Tomosynthesis Mammographic Imaging Screening Trial.

  • Dana-Farber wins legal dispute over PD-1/PD-L1 patents; BMS set to lose exclusive license

    So, you’ve finished your copy of the Mueller Report and you long for another great read from the same publisher—the U.S. government.

  • Review

    Chernobyl, the HBO miniseries: Fact and fiction (Part II)

    Last week, I discussed events resulting in the Chernobyl NPF accident, including unique aspects of the reactor-design which contributed to the accident, and which resulted in release of radiation to the environment. I also discussed the initial Soviet response. Next, I focus on the immediate medical consequences and the response of Soviet government to medical interventions.

  • In Brief

    • Mullighan named deputy director of St. Jude
    • Dimopoulos and Mateos to receive achievement awards from IMF
    • Singh named sub-PI Heartland Cancer Research NCORP Executive Committee
    • Douglas Lowy receives NYU honorary degree
  • Funding Opportunities

    Astellas Oncology calls for entries to C3 Prize to award $200,000

    Astellas Pharma Inc. is calling for entries for the fourth annual Astellas Oncology C3 Prize (Changing Cancer Care), a challenge that funds the best non-treatment ideas to improve cancer care for patients, caregivers and their loved ones.

  • TCCL Logo

  • Clinical Roundup

    • UPenn study shows adding bevacizumab improves OS in NSCLC
    • NRG Oncology phase III study results: partial breast irradiation is effective
    • First states to expand Medicaid saw larger screening rate increases
  • Drugs & Targets

    • Oncopeptides to submit NDA for melflufen in multiple myeloma